title: Systemic methotrexate for the treatment of psoriasis.
abstract: In the era of biologic therapies, methotrexate (MTX), a classic immunomodulator, is still the cornerstone of systemic treatment of psoriasis. MTX has been used for many years, achieving good responses with a good safety profile. However, only a few randomized clinical trials have been performed involving MTX, and most of the current evidence comes from pivotal studies of biologic drugs. The aim of this article is to make an extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics.
authors.affiliation: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain.
authors.forename: Oriol
authors.initials: O
authors.lastname: Yélamos
authors.forename: Lluís
authors.initials: L
authors.lastname: Puig
mesh_terms: D000818:Animals; D001682:Biological Availability; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents; D008727:Methotrexate; D027425:ATP-Binding Cassette, Sub-Family C Proteins
keywords: adenosine; dihydrofolate reductase inhibitor; folic acid; methotrexate; methotrexate polyglutamates; pharmacogenetics; psoriasis